A study of hypertension within an animal model showed that the treatment with a P38 MAPK inhibitor can significantly reduce OPN protein expression in target organs, suggesting that enhanced OPN expression is reflective of end-organ damage in hypertension, and that its suppression therefore correlates with end-organ protection [13]. The gene discussed is SPP1; the disease is hypertensive disorder.